Hip fracture evaluation with alternatives of total hip arthroplasty versus hemiarthroplasty (HEALTH): protocol for a multicentre randomised trial by Bhandari, Mohit et al.
Marshall University
Marshall Digital Scholar
Orthopaedics Faculty Research
Winter 12-11-2014
Hip fracture evaluation with alternatives of total hip
arthroplasty versus hemiarthroplasty (HEALTH):
protocol for a multicentre randomised trial
Mohit Bhandari
P. J. Devereaux
Thomas A. Einhorn
Lehana Thabane
Emil H. Schemitsch
See next page for additional authors
Follow this and additional works at: http://mds.marshall.edu/sm_orthopaedics
Part of the Orthopedics Commons
This Article is brought to you for free and open access by the Faculty Research at Marshall Digital Scholar. It has been accepted for inclusion in
Orthopaedics by an authorized administrator of Marshall Digital Scholar. For more information, please contact zhangj@marshall.edu.
Recommended Citation
Bhandari M, Devereaux PJ, Einhorn TA, et al. Hip fracture evaluation with alternatives of total hip arthroplasty versus
hemiarthroplasty (HEALTH): protocol for a multicentre randomised trial. BMJ Open 2015;5:e006263. doi:10.1136/bmjopen-2014-
006263
Authors
Mohit Bhandari, P. J. Devereaux, Thomas A. Einhorn, Lehana Thabane, Emil H. Schemitsch, Kenneth J. Koval,
Frede Frihagen, Rudolf W. Poolman, Kevin Tetsworth, Ernesto Guerra-Farfán, Kim Madden, Sheila Sprague,
Gordon Guyatt, Ali Oliasharazi, Franklin D. Shuler, Jonathon Salva, James Day, Tigran Garabekyan, Felix
Cheung, Linda Morgan, Timothy Wilson-Byrne MD, and Mary Beth Cordle
This article is available at Marshall Digital Scholar: http://mds.marshall.edu/sm_orthopaedics/14
Hip fracture evaluation with alternatives
of total hip arthroplasty versus
hemiarthroplasty (HEALTH): protocol
for a multicentre randomised trial
Mohit Bhandari,1 P J Devereaux,2 Thomas A Einhorn,3 Lehana Thabane,4
Emil H Schemitsch,5 Kenneth J Koval,6 Frede Frihagen,7 Rudolf W Poolman,8
Kevin Tetsworth,9 Ernesto Guerra-Farfán,10 Kim Madden,11 Sheila Sprague,12
Gordon Guyatt,4 HEALTH Investigators
To cite: Bhandari M,
Devereaux PJ, Einhorn TA,
et al. Hip fracture evaluation
with alternatives of total hip
arthroplasty versus
hemiarthroplasty (HEALTH):
protocol for a multicentre
randomised trial. BMJ Open
2015;5:e006263.
doi:10.1136/bmjopen-2014-
006263
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2014-006263).
Received 13 August 2014
Revised 25 November 2014
Accepted 11 December 2014
For numbered affiliations see
end of article.
Correspondence to
Dr Mohit Bhandari;
bhandam@mcmaster.ca
ABSTRACT
Introduction: Hip fractures are a leading cause of
mortality and disability worldwide, and the number of
hip fractures is expected to rise to over 6 million per
year by 2050. The optimal approach for the surgical
management of displaced femoral neck fractures
remains unknown. Current evidence suggests the use
of arthroplasty; however, there is lack of evidence
regarding whether patients with displaced femoral neck
fractures experience better outcomes with total hip
arthroplasty (THA) or hemiarthroplasty (HA). The
HEALTH trial compares outcomes following THA versus
HA in patients 50 years of age or older with displaced
femoral neck fractures.
Methods and analysis: HEALTH is a multicentre,
randomised controlled trial where 1434 patients,
50 years of age or older, with displaced femoral neck
fractures from international sites are randomised to
receive either THA or HA. Exclusion criteria include
associated major injuries of the lower extremity, hip
infection(s) and a history of frank dementia. The
primary outcome is unplanned secondary procedures
and the secondary outcomes include functional
outcomes, patient quality of life, mortality and hip-
related complications—both within 2 years of the initial
surgery. We are using minimisation to ensure balance
between intervention groups for the following factors:
age, prefracture living, prefracture functional status,
American Society for Anesthesiologists (ASA) Class
and centre number. Data analysts and the HEALTH
Steering Committee are blinded to the surgical
allocation throughout the trial. Outcome analysis will
be performed using a χ2 test (or Fisher’s exact test)
and Cox proportional hazards modelling estimate. All
results will be presented with 95% CIs.
Ethics and dissemination: The HEALTH trial has
received local and McMaster University Research Ethics
Board (REB) approval (REB#: 06-151).
Results: Outcomes from the primary manuscript will
be disseminated through publications in academic
journals and presentations at relevant orthopaedic
conferences. We will communicate trial results to all
participating sites. Participating sites will communicate
results with patients who have indicated an interest in
knowing the results.
Trial registration number: The HEALTH trial is
registered with clinicaltrials.gov (NCT00556842).
INTRODUCTION
The number of hip fractures globally is
expected to rise to over 6 million by the year
2050.1 2 Owing to projected ageing of the
Strengths and limitations of this study
▪ This study has a large sample size of 1434
patients in order to detect small but important
differences in outcomes.
▪ We are utilising an expertise-based randomised
controlled trial design to help to eliminate differ-
ential performance and differential outcome
assessments, and to reduce crossovers and
ethical concerns associated with randomisation.
▪ The study has stringent methodological safe-
guards against bias including: use of a centra-
lised randomisation system; blinding data
analysts and the Steering Committee; standard-
isation and documentation; use of strategies to
limit loss to follow-up; and adjudication of trial
events by an independent Central Adjudication
Committee.
▪ Surgeons and patients cannot be blinded to the
surgical arms, leaving the assessment of out-
comes and decisions to reoperate vulnerable to
bias.
▪ We do not allow family members and friends to
answer questionnaires on behalf of cognitively
impaired patients; so some secondary outcomes
will only apply to patients who are not cogni-
tively impaired.
▪ The 2-year follow-up limits the study to shorter
term outcomes.
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population, the number of hip fractures is likely to
exceed 500 000 annually in the USA and 88 000 in
Canada over the next 40 years.3–5 By the year 2040, the
estimated annual healthcare costs associated with hip
fractures will reach $9.8 billion in the USA and $650
million in Canada.6 Hip fractures account for more hos-
pital days than any other musculoskeletal injury and rep-
resent more than two-thirds of all hospital days due to
fractures.7 In the elderly, hip fractures are associated
with a 30% mortality rate of 1 year postinjury, and tem-
porary8 and often permanent impairment of independ-
ence and quality of life.9 10 Worldwide, 4.5 million
people are disabled from hip fractures yearly; the
number of persons living with disability is expected to
increase to 21 million in the next 40 years.1 3 5 The dis-
ability adjusted life-years lost as a result of hip fractures
ranks in the top 10 of all causes of global disability.3
Inconclusive clinical evidence
Femoral neck fractures may be either non-displaced
(ie, very little separation at the fracture site, about
one-third of femoral neck fractures) or displaced (ie,
greater separation at the fracture site, about two-thirds
of femoral neck fractures). Orthopaedic surgeons often
treat non-displaced fractures with internal fixation and
displaced fractures with arthroplasty, which is also known
as joint replacement.
We conducted a comprehensive literature search to
identify all studies investigating total hip arthroplasty
(THA; involves replacing the femoral head and the acet-
abulum) compared to hemiarthroplasty (HA; involves
replacing the femoral head only) for displaced femoral
neck fractures. We identified a recent meta-analysis of 14
studies (N=1890 patients).11 This meta-analysis demon-
strated a lower risk of reoperation after THA compared
with HA (relative risk 0.57, 95% CI 0.34 to 0.96); however,
this effect was mainly driven by randomised controlled
trials (RCTs) without concealed treatment allocation.
THA consistently resulted in better hip function (Harris
Hip Score, weighted mean difference 5.4, 95% CI 2.7 to
8.2) after follow-up intervals of 12–48 months.11 We also
identified two additional meta-analyses that provide com-
parisons of THA and HA.12 13 Liao et al12 pooled RCTs of
THA (N=403 patients) versus HA (N=425 patients), and
found reductions in the risk of secondary procedures and
wound infection with THA. Furthermore, Liao et al
reported that the mobility rate in THA was better than in
HA. Burgers et al13 performed a meta-analysis of eight
RCTs (N=986 patients) that suggested similar rates of sec-
ondary procedures, 1 year mortality, major complications
and minor complications with THA and HA, but large
benefits in patient function with THA. Despite the bene-
fits that THA confers regarding functional outcomes, sec-
ondary procedures and infection rates, both meta-analyses
reported higher hip dislocation rates with THA.
In a survey of 298 surgeons who were members of the
Orthopaedic Trauma Association or affiliated with AO
International, 94–96% of surgeons agreed that arthro-
plasty is the preferred treatment option in patients over
80 years of age with displaced femoral neck fractures.14
In addition, 73% of surgeons surveyed preferred HA to
THA.14 In summary, current evidence suggests substan-
tial benefits of THA over HA through decreased pain
and improved function, but also increased rates of dis-
location associated with THA, with similar rates of sec-
ondary procedures and mortality with the two
procedures. Despite the apparent benefits of THA over
HA, surgeons more often prefer HA to treat displaced
femoral neck fractures. Previous trials comparing these
two approaches were limited by methodological issues;
therefore, the current trial aims to determine the effect-
iveness of THA compared to HA using a large sample
size and high-quality methodology.
Study objectives
Our primary objective is to assess the impact of THA
versus HA on rates of unplanned secondary procedures
within 2 years for individuals with displaced femoral
neck fractures.
Secondary objectives are:
1. To examine the effect of THA versus HA on
health-related quality of life (Short Form-12, SF-12),
functional outcomes and mobility (Western Ontario
McMaster Osteoarthritis Index, WOMAC, and Timed
Up and Go Test, TUG), and health outcome mea-
sures (EuroQol-5 Dimensions, EQ-5D)
2. To evaluate the effect of THA versus HA on mortality
3. To evaluate the effect of THA versus HA on hip-
related complications, including periprosthetic frac-
ture, hip instability or dislocation, implant failure
(loosening/subsidence and breakage), wound healing
problems (including superficial/deep infection,
wound necrosis), soft tissue problems (eg, pseudotu-
mour), heterotopic ossification, abductor failure,
implant wear and corrosion, osteolysis, neurovascular
injury, decreased function and pain.
METHODS AND ANALYSIS
Overview of study design
HEALTH is a multicentre, concealed RCT of 1434
elderly patients who have sustained a displaced femoral
neck fracture. We are using minimisation, a form of ran-
domisation, to determine patient allocation. Surgeons
across North America, Europe, Australia and Asia are
participating. In conventional surgical hip fracture trials,
all surgeons involved in the trial have performed both
THA and HA based on the randomisation process.
HEALTH utilises an expertise-based randomised trial
design that allocates patients to surgeons with expertise
in THA or HA (figure 1). Based on their expertise, sur-
geons perform either THA or HA. Surgeons who feel
confident enough to perform both surgical strategies
perform both THA and HA.
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Patient selection
Eligibility criteria
The inclusion criteria are: (1) Adult men or women
aged 50 years and older (with no upper age limit);
(2) Fracture of the femoral neck confirmed with antero-
posterior (AP) and lateral radiographs, or CT or MRI;
(3) Displaced fracture that is not, in the judgment of
the attending surgeon, optimally managed by reduction
and internal fixation; (4) Operative treatment within
72 h of the patient being medically cleared for surgery;
(5) Patient was ambulatory prior to fracture, though
they may have used an aid such as a cane or a walker;
(6) Anticipated medical optimisation for arthroplasty of
the hip; (7) Provision of informed consent by patient or
proxy; (8) Low energy fracture (defined as a fall from
standing height); (9) No other major trauma (defined
as an Injury Severity Score <17); and (10) Assurance
that surgeons with expertise in both THA and HA are
available to perform surgery.
The exclusion criteria are: (1) Patient not suitable for
HA (eg, inflammatory arthritis, rheumatoid arthritis,
pathological fracture (secondary to cancer) or severe
osteoarthritis of the hip); (2) Associated major injuries
of the lower extremity (eg, ipsilateral or contralateral
fractures of the foot, ankle, tibia, fibula, knee or femur;
dislocations of the ankle, knee or hip; or femoral head
defects or fracture); (3) Retained hardware around the
affected hip that will interfere with arthroplasty;
(4) Infection around the hip (soft tissue or bone);
(5) Patients with a disorder of bone metabolism other
than osteoporosis (eg, Paget’s disease, renal osteodystro-
phy, osteomalacia); (6) Patients with a previous history
of frank dementia that would interfere with assessment
of the primary outcome (ie, secondary procedures at
2 years); (7) Likely problems, in the judgement of the
investigators, with maintaining follow-up (eg, patients
with no fixed address, report a plan to move out of
town, alcohol abuse issues or intellectually challenged
patients without adequate family support); and
(8) Patients whose fracture occurred as a result of an act
of violence.
Patient recruitment and screening
The first patient was randomised into the vanguard
phase of this trial on 21 January 2009. After a brief
pause in enrolment between the vanguard and definitive
phase, the first definitive patient was randomised on 8
October 2013. Enrolment is ongoing at the time of pub-
lication and is expected to be completed by December
2016. All patients presenting to participating surgeons
with a diagnosed femoral neck fracture amenable to
arthroplasty are screened for participation in the
HEALTH trial. Such patients are classified as:
(1) Excluded (if they do not meet the eligibility cri-
teria); (2) missed (presumed eligible but missed due to
error or staff availability); or (3) included (eligible and
randomised). Study personnel obtain informed consent
from all eligible patients. If a patient lacks capacity and
is deemed unable to consent, study personnel may
obtain informed consent from the patient’s legally
authorised representative and assent from the patient.
Randomisation
We are ensuring concealment of allocation by using a
centralised 24 h computerised randomisation system that
will allow internet-based randomisation. Patients are the
unit of randomisation. To protect against prognostic
imbalance between groups, we are using minimisation to
ensure balance between intervention groups for several
patient factors. The minimisation approach takes into
account each preidentified prognostic variable and sums
over the variables to allocate each patient to the treat-
ment that will minimise the differences between groups
for those prognostic variables. Unlike stratified
Figure 1 Expertise-based
randomised controlled trial.
An expertise-based randomised
controlled trial design randomises
participants to surgeons with
expertise in surgery A or to
surgeons with expertise in
surgery B.
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randomisation, minimisation will work towards minimis-
ing the total imbalance for all factors taken together
instead of considering mutually exclusive subgroups
(strata).15 Based on our international survey of sur-
geons14 and current evidence,16 we are minimising for
the following prognostic factors: (1) Age (ie, 50–80 years
or greater than 80 years); (2) prefracture living setting
(ie, institutionalised or not institutionalised); (3) pre-
fracture functional status (ie, using aid or independent
ambulator); (4) American Society for Anesthesiologists
(ASA) Class (ie, Class I/II or III/IV/V); and (5) partici-
pating centre.
Study interventions
Total hip arthroplasty
In the THA group, we are not including minimally inva-
sive THA (ie, 2 incision approaches) or hinged pros-
theses or capture cups. To optimise feasibility and
applicability of results, we did not standardise the surgi-
cal approach, including the use of cemented compo-
nents, the implant manufacturer or femoral head size.
We are documenting the manufacturer, implant material
and bearing surface of the implant.
Hemiarthroplasty
Surgeons use modern implants for HA, excluding non-
modular and non-canal filling unipolar implants, such as
Moore’s and Thompson’s prostheses. We did not stand-
ardise the choice of modular unipolar versus bipolar HA
nor whether implants are inserted with cement or with a
press-fit design. We are documenting the manufacturer,
implant material and bearing surface of the implant.
Standardisation of procedures and perioperative care
To ensure similar perioperative regimens, we recommend
that participating centres standardise key aspects of pre-
operative and postoperative care. For preoperative
care, we recommend standardisation of the following:
(1) Preoperative antibiotic prophylaxis (eg, cephalospor-
ins or equivalent coverage); (2) thromboprophylaxis (eg,
oral anticoagulation drugs, thromboembolic deterrent
stockings (TEDS), pneumatic compression boots or
medical prophylaxis to be discontinued in sufficient time
to allow for surgery as guided by international normalised
ratio/partial thromboplasty time); and (3) medical con-
sultation to optimise condition prior to surgery. For post-
operative care, we recommend standardisation of the
following: (1) Antibiotic prophylaxis (eg, cephalosporin
or equivalent) for 24 h; (2) thromboprophylaxis with
unfractionated heparin, low-molecular-weight heparin
(LMWH), warfarin, antiplatelet agents or intermittent
pneumatic compression boots; (3) weight-bearing as tol-
erated will be allowed as patients autoprotect the affected
hip during rehabilitation. Postsurgery, patients are
weight-bearing as tolerated and then advanced according
to the attending surgeon’s best judgment; (4) 600 mg
calcium by mouth daily and 1000 IU vitamin D per day
(provided there are no contraindications), and further
investigation and treatment of osteoporosis as recom-
mended by a local osteoporosis expert/consultant; and
(5) appropriate nutritional assessment with administra-
tion of oral micronutrient feeds as needed. Owing to a
lack of evidence favouring a particular approach, we are
recording but did not standardise the following: (1) Use
of preoperative traction; (2) surgical delay; (3) type of
anaesthetic (ie, general or regional); and (4) patient par-
ticipation in physiotherapy and rehabilitation.
Study outcomes
Primary study outcome
The primary outcome is any unplanned secondary pro-
cedure within 2 years of the initial hip replacement
surgery. A Central Adjudication Committee (CAC) will
review each reported secondary procedure to determine
that they are study events (ie, unplanned), and they will
confirm the type of the procedure and the reason for
the procedure (table 1).
Secondary study outcomes
Secondary outcomes include: (1) Functional outcome
and quality of life measured using self-administered and
interview-administered questionnaires. (2) The effect of
THA versus HA on mortality; (3) hip-related complica-
tions including periprosthetic fracture, hip instability or
dislocation, implant failure (loosening/subsidence and
breakage), wound healing problems (including superfi-
cial/deep infection, wound necrosis), soft tissue pro-
blems (eg, pseudotumour), heterotopic ossification,
abductor failure, implant wear and corrosion, osteolysis,
neurovascular injury, decreased function or pain.
Functional outcome and quality of life are measured
using self-administered and interview-administered ques-
tionnaires. Functional outcome questionnaires include a
generic health status measurement instrument (SF-12),17
a hip function and pain questionnaire (WOMAC),18 a
health outcome measure (EQ-5D)19 and a functional
mobility test (TUG).20
The SF-12 questionnaire is a self-administered, 12-item
questionnaire that measures health-related quality of life
in eight domains. Both physical and mental summary
scores can be obtained. Each domain is scored separ-
ately from 0 (lowest level) to 100 (highest level). The
instrument has been extensively validated and has
demonstrated good construct validity, high internal con-
sistency and high test–retest reliability.21 It is frequently
used in orthopaedics for evaluating fracture outcomes.
The WOMAC index is self-administered and assesses
the three dimensions of pain, disability and joint stiff-
ness in knee and hip osteoarthritis using a battery of 24
questions.18 It is a valid, reliable and responsive measure
of outcome and has been used in several studies involv-
ing a wide range of lower extremity conditions.22
The EQ-5D is a comprehensive, compact health status
classification and health state preference system.19 This
questionnaire is widely used, and has demonstrated
validity and sensitivity in many populations.19 21
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The EQ-5D is generalisable as it is widely used in
Europe and will be useful for our definitive trial in
which we will be including international sites.
The TUG involves observing the patient and docu-
menting the time,20 in seconds, it takes for the patient
to rise from a standard armchair, walk to a line on the
floor 3 m away, turn, return and sits down again. The
TUG has been used in many clinical contexts, including
orthopaedics,23 rheumatology24 and for predicting geri-
atric falls.25
Adjudication of study events
The HEALTH CAC is comprised of five orthopaedic sur-
geons who specialise in hip surgery and have expertise
in research methodology and experience with clinical
trials. The CAC are reviewing: (1) Cases where fracture
eligibility is in doubt; (2) postoperative X-rays to assess
the technical placement of prostheses; (3) all reported
secondary procedures and fracture-related complications
to determine if the secondary procedure and/or
fracture-related complication meets the requirements of
the study criteria; and (4) cases of mortality to confirm
the cause of death. All centres submit digital X-rays
to the HEALTH Methods Centre. We post all relevant
patient records devoid of personal identifiers (ie, case
report forms and X-rays) on a specially designed,
password-protected website for study adjudication.
Adjudication occurs after patients have completed their
2 year follow-up. Any disagreements among the CAC
members are resolved during conference calls. All deci-
sions made by the Committee are final.
Study follow-up
All patients are followed for a period of 2 years. At each
follow-up interval, patients’ health status and outcomes
are recorded. In addition, during the 2-year follow-up
visit, the surgeon documents any secondary procedure
that may be planned for the patient. Figure 2 shows the
schedule of events and assessments at each time point.
Our choice of a 2-year follow-up period is dictated by
two factors. First, previous studies have reported that
75% of revision surgeries occur before 12 months for
patients treated with arthroplasty for displaced femoral
neck fractures.26 Thus, we can expect that the majority
of revision surgeries will occur within 2 years. Since
increasing follow-up to beyond 2 years will yield little
additional information on secondary procedure rates,
efficient use of resources dictates a 2-year follow-up.
Second, a full 2 years of follow-up will provide sufficient
time to assess any potential gains in function and quality
of life provided by either surgical alternative.
Protecting against sources of bias
Blinding
While surgeons, patients and outcome assessors cannot
be blinded to the surgical arms (ie, THA or HA), data
analysts and the Steering Committee will remain blinded
throughout the trial. Secondary procedures, the primary
outcome, are objective and lack of blinding introduces
minimal threats to validity. Additionally, the HEALTH
trial design eliminates differential expertise bias by estab-
lishing a minimal threshold for experience, as well as
ensuring that all surgeons, performing either THA or
HA, are dedicated to and have sufficient expertise with
the procedure.
Surgeon expertise
Surgeons participating in the HEALTH trial are asked to
meet both of the following two criteria of expertise for
either THA or HA: (1) Perform at least 50 procedures
Table 1 Classification of types and reasons for unplanned secondary procedures
Specific unplanned secondary procedures include
Classification of the reason for secondary
procedures is as follows
▸ Closed reduction of hip dislocation
▸ Open reduction of hip dislocation
▸ Open reduction of fracture
▸ Soft tissue procedure
▸ Insertion of antibiotic spacer
▸ Full implant exchange
▸ Partial implant exchange—stem only
▸ Partial implant exchange—head only
▸ Partial implant exchange—liner only
▸ Partial implant exchange—head and liner
▸ Partial implant exchange—acetabular component only
▸ Partial implant exchange—acetabular component and head
▸ Implant adjustment—re-orientation of the stem
▸ Implant adjustment—re-orientation of the acetabulum
component
▸ Implant removal with no replacement
▸ Excision heterotopic ossification
▸ Supplementary fixation
▸ Treat a periprosthetic fracture
▸ Treat hip instability or dislocation
▸ Treat infection—superficial
▸ Treat infection—deep
▸ Treat wound necrosis
▸ Treat another wound healing problem
▸ Remove heterotopic ossification
▸ Manage abductor failure
▸ Manage another soft tissue problem (ie,
pseudotumour)
▸ Correct implant failure—loosening or subsidence
▸ Correct implant failure—breakage
▸ Treat implant wear
▸ Treat osteolysis
▸ Treat implant corrosion
▸ Improve function
▸ Relieve pain
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(either THA or HA) in their career (including residency
experience in which they assumed responsibility for the
procedure), and (2) perform at least five procedures
per year. Surgeons who meet the threshold for both
THA and HA will perform both procedures, if no over-
whelming bias in favour of one procedure is evident. A
surgeon is considered biased for an approach if they
performed less than five cases of either procedure in
their last 50 procedures for a displaced femoral neck
fracture. Residents and fellows may perform the proce-
dures under the supervision of a participating attending
surgeon. The surgeon most responsible for the case
must meet the threshold expertise criteria and must be
present in the operating room for the critical aspects of
the procedure (table 2). Our decision to set 50
procedures as the threshold for experience is based on
previous studies examining learning curves and respect-
ive outcomes in patients undergoing THA.27–29 Our
survey of surgeons, who are members of the
Orthopaedic Trauma Association (OTA) or European
AO International trauma centres, suggests that the
threshold of HA is likely similar or slightly lower, given
the perception of increased difficulty of THA.
Devereaux et al30 have outlined the advantages of this
trial design which includes the following:
1. Elimination of differential expertise bias in which, in
conventional designs, a larger proportion of surgeons
are experts in one procedure under investigation
over the other.
2. Differential performance, cointervention, data collec-
tion and outcome assessment are less likely than in
conventional RCT.
With this approach, ethical concerns are reduced
because all surgeries are conducted by surgeons with
expertise and conviction in the concerned procedures.30
Maximising patient retention
Previous trials in hip fracture surgery have lost up to
50% of patients to follow-up.14 To avoid this problem,
the strategies outlined in figure 3 are used to minimise
the loss to follow-up. We have successfully used the
majority of these strategies to maximise follow-up in
other multicentre studies. Key features of this strategy
include: (1) excluding individuals who are likely to
present problems to the follow-up; (2) prior to hospital
discharge, in addition to proving their own contact
Figure 2 Schedule of events. *Complete forms when and/or if applicable.
Table 2 Critical aspects of operative procedure requiring
presence of experienced surgeon
Hemiarthroplasty
▸ Trial component insertion and verification of hip stability
▸ Implant insertion to ensure correct version
▸ Cement procedure, if used
▸ Final assessment of hip stability after implant insertion
Total hip arthroplasty
▸ Trial component insertion and verification of hip stability
▸ Implant insertion to ensure correct alignment of femoral
and acetabular components
▸ Cement procedure, if used
▸ Final assessment of hip stability after implant insertion
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information, each patient provides the name and
address of alternate contacts who are likely to be aware
of the patient’s whereabouts; (3) patients receive a
reminder for their next follow-up visit from the clinical
research coordinator; and (4) follow-up visits coincide
with standard fracture clinic visits. Additionally, patients
can complete some study visits over the phone provided
no radiographs are required.
Minimising cointerventions and contamination
Any patients who cross over from one treatment group
to the other will be analysed in the group to which they
were allocated, maintaining the intention to treat
approach of the analysis. Surgical cointerventions, such
as general, neurosurgical or orthopaedic procedures,
performed in addition to the arthroplasty procedure
have the potential to confound outcomes. The standard-
isation of key aspects of preoperative and postoperative
care, together with the expertise-based trial design, will
minimise the use of cointerventions in study patients.
Clinical sites record the details of any major additional
procedures performed, as well as the use of medications
that affect bone, such as bisphosphonates, vitamin D,
calcium, hormone replacement therapy, selective
oestrogen receptor modulators, calcitonin and anabolic
steroid therapy.
Maximising protocol adherence
Given the inherent variability in practice patterns
among orthopaedic surgeons, we believe it is important
to ensure that surgeons adhere as closely as possible to
the surgical management protocol. The feasibility of this
large study involving multiple centres further depends
on minimal changes from current practice. Our study
protocol closely follows currently accepted practice in
the management of patients with femoral neck fractures.
We, therefore, anticipate high compliance with our
protocol.
Statistical plan
Sample size determination
The choice of sample size is based on a comparison of
THA versus HA for the primary outcome (unplanned
secondary procedures). All statistical hypotheses will be
two-sided. α Levels of 0.05 for the primary and 0.01 for
the secondary outcomes were chosen. Previous studies
have reported secondary procedure rates in hip fracture
patients treated with HA that have ranged from 4% to
Figure 3 Strategies to enhance follow-up rates.
Bhandari M, et al. BMJ Open 2015;5:e006263. doi:10.1136/bmjopen-2014-006263 7
Open Access
group.bmj.com on October 30, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
10% within 1 year, with a weighted pooled risk of 5.3%
(95% CI 3.2% to 8.9%) in a fixed effect meta-analysis or
4.9% (95% CI 2.6% to 9.2%) using random effects.13
A pooled estimate from five randomised trials compar-
ing THA with HA gave a relative risk of 1.67 (95% CI
0.86 to 3.24, p=0.13; table 3).13 31–35
The sample size calculation reflects the proposed
approach to the primary analysis, which will use the Cox
proportional hazards model. The calculation is based on
methods described by Collett.36 The goal is to calculate
the required number of patients that will yield a suffi-
cient number of outcome events (secondary proce-
dures) in order to have adequate statistical power for a
given size of treatment effect. This was performed taking
into account the anticipated secondary procedure rates
in the HA group, postulated values of the relative risk
increase associated with THA versus HA, and the rates of
mortality and loss to follow-up. Since some of these
inputs are expected to change over the 2-year period of
follow-up, the expected number of person-years of
follow-up and the expected numbers of study events in
each group were calculated, initially for the first year of
follow-up; the calculation was then repeated for the
second year of follow-up, after having estimated the
number of patients in each group who would survive, be
event-free and available for continued follow-up between
12 and 24 months postrandomisation.
Based on aggregate data from the pilot study, annual
mortality rates of 15% and a loss to follow-up of 5% in
each group were assumed, these rates applying to each
of the 2 years of follow-up. Informed by the
meta-analysis, the following assumptions were made: a
1 year risk of having a secondary procedure of 5% in the
HA group and a corresponding risk of 1% in the second
year. Various values of the relative risk reduction (HA vs
THA) were then used to identify the specific value that
would correspond to a cumulative risk difference
between THA and HA of 5% after 2 years. This figure
was identified in a survey of participating surgeons as
the minimally important difference to clinicians (unpub-
lished data). Annual event risks by group were converted
into equivalent hazard rates, assuming for simplicity that
the hazard rate would be approximately constant during
each of the 2 years. It is estimated that approximately
72% of the group receiving THA and 76% of the group
receiving HA will be event-free and available for further
follow-up at the start of the second year. The sample size
was increased to allow for a combined 7.6% crossover
rate from the assigned to the alternate treatment, based
on pilot data. These assumptions lead to a required total
sample size of 1316 patients, which will yield an
expected number of 96 secondary procedures. The asso-
ciated relative risk reduction (RRR) is 0.45. These calcu-
lations were repeated after replacing the 5% event risk
at 1 year for HA by 4% and 6% and leaving the other
factors unchanged (table 4). To account for potential
surgeon level effects, the sample size has been further
increased by 9% to 1434.
For the secondary outcomes, an important difference
in SF-12 is considered to correspond to a moderate
effect, as reported by Cohen, and to a minimally import-
ant difference in the SF-12 as reported by Ware.37 38 In
both cases, the value is at least half the SD, equivalent to
4-point difference in score. Specifying α level=0.05,
β=0.20 (study power=80) and a SD of 8,39 a sample of at
least 128 patients (64 per group) is required to ensure
detection of a half SD improvement. In clinical drug
trials, a 9-point change in WOMAC functional score was
accepted as a minimally significant improvement in
symptoms.40 In this study, at least 90 patients (45 per
group) would be required to detect this difference
(α level=0.05, β=0.20, σ=15). Previous studies have found
a SD of 0.20 for the EQ-5D.41 To detect a difference of
0.10 (half the SD) with 80% power at α level of 0.05, this
study requires a total of 128 patients (64 per group).
Thus, in all circumstances, the desired sample size of
1434 patients will be sufficient to detect clinically mean-
ingful differences in the secondary measures of
outcome.
Primary analyses
All outcome analyses will be performed by an intention-
to-treat approach. To evaluate the effect of THA versus
HA on time to unplanned secondary procedures (the
Table 4 Sample size calculations comparing total hip
arthroplasty (THA) and hemiarthroplasty (HA)
HA 1 year
event risk
Total patients
required
Expected
events (n) RRR
4% 1123 72 0.50
5% 1316 96 0.45
6% 1435 108 0.42
Sample size requirement for HEALTH Pivotal Trial (non-inferiority
design).
RRR, relative risk reduction.
Table 3 Sample size calculations comparing total hip
arthroplasty (THA) and hemiarthroplasty (HA)
Study
THA reoperation
rate
HA reoperation
rate
van den Bekerom
et al31
5/110 (4.5%) 1/136 (0.7%)
Baker et al32 4/36 (11.1%) 2/39 (5.1%)
Blomfeldt et al33 4/56 (7.1%) 3/57 (5.3%)
Keating et al34 6/63 (9.5%) 5/64 (7.8%)
Macaulay et al35 1/16 (6.25) 0/23 (0%)
Studies included in a meta-analysis comparing THA with HA for
the outcome of reoperation at 1 year.
THA versus HA combined effect: fixed and random, relative
risk=1.67 (95% CI 0.86 to 3.24), p=0.13.
Pooled event rates: THA fixed and random, incidence rate=7.8%
(95% CI 5.2 to 11.6).
HA fixed, incidence rate=5.3% (95% CI 3.2 to 8.9).
HA random, incidence rate=4.9% (95% CI 2.6 to 9.2).
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primary outcome), a Cox proportional hazards model
will be used with the following covariates: (1) Age (ie,
50–80 years or >80 years); (2) prefracture living setting
(ie, institutionalised or not institutionalised); (3) pre-
fracture functional status (ie, using aid or independent
ambulator); (4) American Society for Anesthesiologists
(ASA) Class (ie, Class I/II or III/IV/V); and (5) partici-
pating centre. Results will be reported as HRs with 95%
CIs. Kaplan-Meier curves will be constructed.
Secondary analyses
In the secondary analysis, we will adjust for additional
baseline factors when examining the effect of THA
versus HA on time to unplanned secondary procedures
(the primary outcome). This will be a Cox proportional
hazards model which will include the same variables
that are included in our primary analysis and addition-
ally adjust for (1) gender, (2) surgical approach and
(3) head size, by including these as independent vari-
ables. Results will be reported as HRs with 95% CIs.
A generalised linear model will estimate the effect of
THA versus HA on quality of life (SF-12), function
(WOMAC), health outcome (EQ-5D), and mobility
(TUG) at follow-up using the following covariates that
are included in our minimisation procedure: (1) Age
(50–80 years or greater than 80 years); (2) prefracture
living setting (ie, institutionalised or not institutiona-
lised); (3) prefracture functional status (ie, using aid or
independent ambulator); (4) ASA Class (ie, Class I/II or
III/IV/V); and (5) participating centre.
Cox proportional hazards modelling will estimate the
relative effect of THA versus HA on time to mortality
and hip-related complications. Results will be reported
as HRs with 95% CIs. Kaplan-Meier curves will be
constructed.
Interim analyses
The approach to interim analyses is guided by a desire
to avoid spuriously inflated estimates of treatment
effect.42 A single interim analysis will be performed
when 60% of the planned patient-years of follow-up
have been accrued. The data analyst will present the
results of these analyses to our independent Data
Monitoring Committee. The committee will be guided
by the O’Brien-Fleming stopping rule based on the
primary outcome, which will maintain the overall speci-
fied type I error rate at 5% for the combined interim
and final analyses. According to this rule, the required p
value to declare a significant result in the interim ana-
lysis is 0.007 and at the final analysis, the required p
value is 0.047. The rule is conservative, making it diffi-
cult to stop the trial early unless a large treatment effect
is observed. We will only apply our stopping rule to the
primary outcome. The secondary functional outcomes
may demonstrate significance quickly due to the nature
of the instruments, but we will not stop the study for
that reason. No one other than committee members will
be aware of the data on which the committee makes its
decision and no one involved in the study will be aware
of the content of their deliberations.
Data management
The case report forms (CRFs) are the primary data col-
lection tool for the study. An Electronic Data Capture
system (iDataFax) is being used to submit data to the
Methods Centre located at McMaster University. On
receipt of the data, the personnel at the Methods
Centre make a visual check of the data and they query
all missing data, implausible data and inconsistencies.
Sensitivity analyses
We will perform some sensitivity analyses to assess the
robustness of the primary results. First, we will perform a
competing risk analysis using Fine and Gray method to
account for death as a competing risk.43 Second, we will
use the random-effects analysis with a centre as a
random-effect to account for the possibility of the centre
effect or clustering within a centre. Lastly, based on the
pilot results, we anticipate some crossovers during the
trial—we will monitor these and perform some sensitiv-
ity analysis to assess their impact. All analyses will be per-
formed using SAS V.9.2 (Cary, North Carolina, USA).
Missing data
Patients who are lost or withdrawn from the study prior
to the full 24 month follow-up will be censored at their
last visit where evaluation of the primary end point was
completed.
Data monitoring committee
The purpose of the Data Monitoring Committee (DMC)
is to advise the HEALTH Investigators regarding the con-
tinuing safety of study participants. The DMC consists of
the Chair, who is an orthopaedic surgeon, one biostatis-
tician and two additional orthopaedic surgeons. All
members are independent of the trial investigators, and
have neither financial nor scientific conflicts of interest
with the trial. Further details regarding the DMC can be
found in the DMC Charter, available from the corre-
sponding author.
ETHICAL CONSIDERATIONS
All patients (or their legally authorised representative)
included in this study will sign a consent form that
describes this study and provides sufficient information
for patients to make an informed decision about their
participation. All participating centres will submit the
consent form with the protocol for review and approval
by their local research ethics board (REB), or institu-
tional review board (IRB) for the study. Centres will
obtain written consent from every patient, using the
REB/IRB-approved consent form, before that patient
undergoes any study procedure. Any amendments to the
study protocol which may affect the conduct of the
study, or the potential safety of or benefits to patients
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will require a formal amendment to the protocol requir-
ing approval by McMaster University’s REB and local
research ethics boards for clinical sites. Any protocol
amendments will be communicated to investigators,
REB/IRB, trial participants and trial registries, as
deemed necessary.
Information about study patients will be kept confi-
dential and will be managed in accordance with the fol-
lowing rules: (1) All study-related information will be
stored securely at the clinical site; (2) all study patient
information will be stored in locked file cabinets and be
accessible only to study personnel; (3) all CRFs will be
identified only by a coded patient number and initials;
(4) all records that contain patient names or other iden-
tifying information will be stored separately from the
study records and can be identified only by the coded
patient number and initials; and (5) all local databases
will be password protected.
DISSEMINATION
Results from the primary manuscript will be submitted
for publication regardless of whether or not there are
significant findings. Every attempt will be made to
ensure that the amount of time between completion of
data collection and release of study findings are
minimised.
Only the Methods Centre will have access to the full
trial data set. Data for the primary publication will be
analysed exclusively by the Methods Centre. Requests for
access to the full trial data set for secondary publications
are encouraged and can be initiated through a written
request to Methods Centre personnel.
DISCUSSION
Previous orthopaedic trials have addressed the effect of
THA versus HA on patient outcomes; however, the trials
conducted to date are limited by small sample sizes, lack
of concealed randomisation, differential expertise
biases12 and most were single centre initiatives that
lacked sufficient power to inform surgical practice.
Orthopaedic surgeons appear to currently favour HA,
although current evidence suggests superior patient-
important outcomes with THA.13 30 The HEALTH trial
will aim to resolve these controversies by establishing the
effectiveness of each method of arthroplasty. This will
have important clinical implications as each treatment is
easily applicable and already in use in orthopaedic
practice.
The HEALTH trial will address and overcome many of
the limitations of previous orthopaedic hip fracture
trials. First, the study sample size of 1434 patients is suffi-
cient to detect small but important differences in out-
comes and will ensure that our study objectives are met.
Second, using an expertise-based RCT has many advan-
tages over traditional orthopaedic hip studies, including
eliminating differential performance and differential
outcomes assessment, and reducing the number of
crossovers and ethical concerns associated with random-
isation.12 Furthermore, the HEALTH trial has stringent
methodological safeguards against bias including: the
use of a centralised system to randomise patients; blind-
ing data analysts and the Steering Committee; standard-
isation and documentation of preoperative care,
perioperative care and postoperative care; the use of
strategies to limit loss to follow-up and adjudication of
trial events by an independent CAC.
A key limitation of the HEALTH trial is that surgeons
and patients cannot be blinded to the surgical arms.
This leaves the assessment of outcomes and decisions to
re-operate vulnerable to bias. We have limited this bias
by using an objective primary outcome (unplanned sec-
ondary procedures) and by centrally adjudicating all
primary outcome events using a group of independent
orthopaedic surgeons. Additionally, we do not allow
family members or friends to answer questionnaires on
behalf of cognitively impaired patients; thus, some sec-
ondary outcomes will only apply to patients who are not
cognitively impaired. Our trial is limited to shorter term
outcomes—up to 2 years following the initial surgery.
Therefore, our results may not apply when considering
longer term outcomes.
The results of the HEALTH trial will be an important
contribution to orthopaedic surgical literature and are
likely to lead to changes in orthopaedic practice.
Identifying the optimal approach to arthroplasty has the
potential to improve the lives of hundreds of thousands
of patients and to reduce the economic burden asso-
ciated with hip fractures. If this trial shows that one
approach is superior to the other, it will revolutionise
the treatment of hip fractures globally and may poten-
tially lead to the establishment of new clinical guidelines
for treatment of displaced femoral neck fractures. In
addition to the clinical impact, the HEALTH trial also
has the potential to impact orthopaedic trial conduct.
With this trial we will build collaborative relationships
among countries and between clinical centres. This trial
will also contribute to challenging the dogma that surgi-
cal trials are doomed to be confined to small single
centre initiatives.
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